Thu, Oct 23, 2014, 1:35 AM EDT - U.S. Markets open in 7 hrs 55 mins


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • bigdan1973pa bigdan1973pa May 19, 2011 8:51 AM Flag

    ASCO or Bust Baby!

    Might be a good day!

    Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting
    8:30 am ET 05/19/2011 - Business Wire
    Pre-Clinical Data Show Potential Combinability and Enhanced Anti-Tumor Activity With Two Different Agents

    JERUSALEM & BOTHELL, Wash. & VANCOUVER, British Columbia--(BUSINESS WIRE)--May. 19, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from three studies of their investigational compound custirsen (OGX-011/TV-1011) in castrate resistant prostate cancer (CRPC) will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.

    Custirsen is the only compound in development designed to inhibit the production of clusterin, a protein commonly over-produced in cancer cells and a potential cause of treatment resistance. Previous clinical data from the Phase II trials demonstrated that custirsen combined with docetaxel improved overall survival rates as well as durable pain palliation

2.19-0.01(-0.45%)Oct 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.